Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com
Otonomy (NASDAQ:OTIC) Earns Hold Rating From Analysts at StockNews.com
StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company's stock.
斯托克新闻网在周六上午发给投资者的一份研究报告中开始对Otmey(纳斯达克:One-Get Rating)的股票进行报道。该公司对这家生物制药公司的股票发布了持有评级。
Separately, Piper Sandler lowered shares of Otonomy from an overweight rating to a neutral rating and dropped their price target for the company from $3.00 to $0.50 in a research note on Thursday, October 13th.
另外,派珀·桑德勒在10月13日(星期四)的一份研究报告中将Otmey的股票评级从增持下调至中性,并将该公司的目标价从3.00美元下调至0.50美元。
Otonomy Price Performance
高性价比
Shares of Otonomy stock opened at $0.07 on Friday. The firm has a market capitalization of $4.23 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 52 week low of $0.06 and a 52 week high of $2.59. The firm's 50 day moving average is $0.11 and its two-hundred day moving average is $0.68.
上周五,Otmey的股票开盘报0.07美元。该公司的市值为423万美元,市盈率为-0.10,贝塔系数为1.31。Otomy的52周低点为0.06美元,52周高位为2.59美元。该公司的50日移动均线切入位在0.11美元,200日移动均线切入位在0.68美元。
Hedge Funds Weigh In On Otonomy
对冲基金对Otmey的看法
Otonomy Company Profile
Otmey公司简介
(Get Rating)
(获取评级)
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Otomy,Inc.是一家生物制药公司,在美国开发神经学疗法。该公司提供治疗耳鸣的N-甲基-D-天冬氨酸受体拮抗剂Gacycldine的持续暴露制剂OTO-313,以及治疗耳鸣的脑源性神经营养因子持续暴露制剂OTO-413,该制剂处于第二阶段临床试验,用于修复耳蜗突触和治疗噪音中语音听力困难。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Three Healthcare Penny Stocks to Watch In The New Year
- Southwest Airlines Stock, There is a Lot to Love
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- 免费获取StockNews.com关于OTMy的研究报告(OTIC)
- 新年值得关注的三只医疗保健便士股
- 西南航空公司股票,有很多值得爱的东西
- MarketBeat:回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温,标普500指数何去何从
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收《Otmey Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对Otmey及相关公司评级的每日简要摘要。